Abstract:Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been demonstrated to alleviate non-alcoholic fatty liver disease (NAFLD). However, the underlying mechanism has not been fully elucidated. Increasing evidence suggests that autophagy is involved in the pathogenesis of hepatic steatosis. In this study, we examined whether liraglutide could alleviate hepatic steatosis through autophagy-dependent lipid degradation and investigated the underlying mechanisms. Herein, the effects of liraglutide on NAFLD were evaluated in a high-fat diet (HFD)-induced mouse model of NAFLD as well as in mouse primary and HepG2 hepatocytes exposed to palmitic acid (PA). The expression of the GLP-1 receptor (GLP-1R) was measured in vivo and in vitro . Oil red O staining was performed to detect lipid accumulation in hepatocytes. Electron microscopy was used to observe the morphology of autophagic vesicles and autolysosomes. Autophagic flux activity was measured by infecting HepG2 cells with mRFP-GFP-LC3 adenovirus. The roles of GLP-1R and transcription factor EB (TFEB) in autophagy-lysosomal activation were explored using small interfering RNA. Liraglutide treatment alleviated hepatic steatosis in vivo and in vitro . In models of hepatic steatosis, microtubule-associated protein 1B light chain-3-II (LC3-II) and SQSTM1/P62 levels were elevated in parallel to blockade of autophagic flux. Liraglutide treatment restored autophagic activity by improving lysosomal function. Furthermore, treatment with autophagy inhibitor chloroquine weakened liraglutide-induced autophagy activation and lipid degradation. TFEB has been identified as a key regulator of lysosome biogenesis and autophagy. The protein levels of nuclear TFEB and its downstream targets CTSB and LAMP1 were decreased in hepatocytes treated with PA, and these decreases were reversed by liraglutide treatment. Knockdown of TFEB expression compromised the effects of liraglutide on lysosome biogenesis and hepatic lipid accumulation. Mechanistically, GLP-1R expression was decreased in HFD mouse livers as well as PA-stimulated hepatocytes, and liraglutide treatment reversed the downregulation of GLP-1R expression in vivo and in vitro . Moreover, GLP-1R inhibition could mimic the effect of the TFEB downregulation-mediated decrease in lysosome biogenesis. Thus, our findings suggest that liraglutide attenuated hepatic steatosis via restoring autophagic flux, specifically the GLP-1R-TFEB-mediated autophagy-lysosomal pathway.

Liraglutide, a TFEB-Mediated Autophagy Agonist, Promotes the Viability of Random-Pattern Skin Flaps

FGF21 augments autophagy in random-pattern skin flaps via AMPK signaling pathways and improves tissue survival

Effects Of Liraglutide On The Survival Of Random Skin Flaps In Rats: An Experimental Study

A Snake Cathelicidin Enhances Transcription Factor EB-mediated Autophagy and Alleviates ROS-induced Pyroptosis after Ischaemia-Reperfusion Injury of Island Skin Flaps

Gastrodin Promotes the Survival of Random-Pattern Skin Flaps via Autophagy Flux Stimulation

Empagliflozin promotes skin flap survival by activating AMPK signaling pathway

Cyclic Helix B Peptide Promotes Random‐pattern Skin Flap Survival Via TFE3‐mediated Enhancement of Autophagy and Reduction of ROS Levels

Baicalin promotes random‐pattern skin flap survival by inducing autophagy via AMPK‐regulated TFEB nuclear transcription

Nuciferine improves random skin flap survival via TFEB-mediated activation of autophagy-lysosomal pathway

Chemically Modified SDF-1α mRNA Promotes Random Flap Survival by Activating the SDF-1α/CXCR4 Axis in Rats

Celastrol enhances the viability of random‐pattern skin flaps by regulating autophagy through the AMPK‐mTOR‐TFEB axis

Exenatide inhibits necrosis by enhancing angiogenesis and ameliorating ischemia/reperfusion injury in a random skin flap rat model

Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism

IGF-PLGA microspheres promote angiogenesis and accelerate skin flap repair and healing by inhibiting oxidative stress and regulating the Ang 1/Tie 2 signaling pathway

Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway

Positive Effect of Andrographolide Induced Autophagy on Random-Pattern Skin Flaps Survival

Tetrahydropalmatine promotes random skin flap survival in rats via the PI3K/AKT signaling pathway

Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5

Curcumin promotes the survival of ischemic random skin flaps via autophagy

Puerarin enhances TFEB-mediated autophagy and attenuates ROS-induced pyroptosis after ischemic injury of random-pattern skin flaps

Rosuvastatin Promotes Survival of Random Skin Flaps Through AMPK-mTOR Pathway-Induced Autophagy.